Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. (Nasdaq: SRTS) is a leading medical device company dedicated to providing non-invasive and cost-effective treatments for non-melanoma skin cancer and keloids. Utilizing a proprietary low-energy x-ray radiation technology known as Superficial Radiation Therapy (SRT), Sensus Healthcare has made significant advancements in the field over more than a decade of dedicated research and development. The company’s flagship products, the SRT-100™ and SRT-100 Vision™, effectively and safely treat a variety of oncological and non-oncological skin conditions, including basal cell and squamous cell skin cancers, as well as keloids.
Based in Boca Raton, Florida, Sensus Healthcare focuses on creating innovative, minimally-invasive solutions that address critical medical needs. The company has recently announced a multi-faceted collaboration with CureRays, a radiation oncology specialist organization headquartered in Atlanta and Grass Valley, California. This partnership aims to enhance the reach and efficacy of Sensus's SRT technology, further solidifying its position as a leader in the non-invasive treatment market.
Sensus Healthcare generates the majority of its revenue from customers within the United States, offering products and services that meet the highest standards of safety and effectiveness. The company’s proprietary technology has been incorporated into its diverse portfolio, which includes the SRT-100™, SRT-100 Vision™, and a comprehensive Sentinel service program that ensures optimal device performance and customer satisfaction.
Investors and stakeholders are encouraged to stay informed about Sensus Healthcare’s latest developments. Recently, the company announced it would hold a conference call on May 9, 2024, to discuss the financial results for the first quarter of 2024 and provide updates on recent and upcoming milestones. This call will offer an in-depth overview of the company’s financial health and strategic initiatives.
For more detailed information about Sensus Healthcare, its innovative technology, products, and recent news, please visit Sensus Healthcare’s official website.
Sensus Healthcare, Inc. (SRTS) reported a remarkable fourth quarter 2021 with revenues of $13.0 million, surging 156% year-over-year. Net income reached $5.3 million or $0.32 per diluted share, compared to $1.0 million or $0.06 in Q4 2020. The full-year revenue climbed to $27.0 million, a 182% increase from 2020. Positive momentum is expected to continue into 2022, bolstered by new product agreements and improved reimbursement rates. Management anticipates profitability for both the first quarter and full year of 2022.
Sensus Healthcare (Nasdaq: SRTS) announced key executive promotions as part of its strategy for long-term growth. Michael J. Sardano has been promoted to President, while Christopher Machuzak and Jeffrey Starling are now Vice Presidents of Sales for the West and East Coasts, respectively. This decision reflects the company's commitment to develop talent internally and enhance its leadership team. The announcement also included the retirement of Executive Vice President and Co-founder Steve Cohen. These changes aim to leverage leadership strengths and drive sustained sales growth, especially post-COVID-19.
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced a conference call on February 10, 2022, at 4:30 p.m. ET to discuss Q4 and full-year 2021 financial results. The call will include a business update and a review of recent and upcoming milestones. Interested parties can join the call via dial-in or a live webcast accessible through the company's website. Sensus Healthcare specializes in non-invasive and minimally invasive treatments through advanced technologies like the Sculptura™ system and SRT-100™ for oncological and non-oncological conditions.
Sensus Healthcare (SRTS) announces participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. CEO Joe Sardano will present a pre-recorded session available on-demand starting January 10 at 7:00 a.m. ET. Attendees can access the presentation via the company’s investor relations page. Additionally, Sensus management is open to virtual 1x1 meetings during the J.P. Morgan Healthcare Conference from January 10-14. Interested parties can schedule meetings through email.
Sensus Healthcare (Nasdaq: SRTS) anticipates achieving record sales exceeding $25 million for 2021, along with positive EBITDA and net income for both Q4 and the full year. The company's growth is attributed to strong performance during the pandemic recovery. Sensus has also begun exclusive U.S. distribution of its newly FDA-cleared TransDermal Infusion System™, which will be presented at the Winter Clinical Dermatology Conference on January 15, 2022. This system aims to enhance drug absorption in non-invasive aesthetics, indicating potential for broader market interest.
Sensus Healthcare (Nasdaq: SRTS) has signed an exclusive U.S. distribution agreement with Mattioli Eng. Italia S.P.A. for its FDA-cleared TransDermal Infusion System, a non-invasive drug delivery technology. Beginning immediately, Sensus will market this system to dermatologists for various applications, such as skin rejuvenation and pre- and post-plastic surgery treatments. The system allows for the painless delivery of drugs like Botox and hyaluronic acid, enhancing patient care and offering a competitive edge in the aesthetic dermatology field.
Sensus Healthcare (SRTS) reported a strong third quarter for 2021, achieving revenues of $5.5 million, a 244% increase from $1.6 million in Q3 2020. This marks the company’s first profitable quarter, with a net income of $0.2 million or $0.01 per diluted share, improving from a net loss of $(1.7) million a year prior. The company shipped 14 systems during the quarter and reaffirmed expectations for continued growth and profitability into Q4 and 2021. Cash reserves stood at $16.4 million with no long-term debt.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on November 4, 2021, at 4:30 p.m. Eastern time to discuss its third quarter 2021 financial results. Management will provide a business update and discuss recent and upcoming milestones. Investors can access the call by dialing 800-285-6670 (U.S.) or 832-553-9961 (International), and the call will also be available via live webcast. Following the call, a replay will be accessible via telephone and online. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will host a virtual fireside chat with CEO Joseph Sardano and CFO Javier Rampolla on October 19, 2021, at 11:00 a.m. ET. This session, organized by Maxim Group LLC and M-Vest, invites professional investors to register in advance. A 48-hour replay will be available post-event on the company’s investor website. Sensus Healthcare specializes in innovative, non-invasive treatments for oncological and non-oncological conditions, including its Sculptura™ system and SRT-100™ technology.
Sensus Healthcare (Nasdaq: SRTS) has received a five-year license renewal from the Chinese Health Authority to market its SRT-100™ system for treating non-melanoma skin cancer and keloids in Greater China. The new license, effective until December 2026, reflects the company's successful presence with 46 units installed in various medical facilities across China. The CEO expressed optimism about post-pandemic sales recovery and remarked on a new distribution agreement with Ekpac Healthcare. Sensus also anticipates marketing authorization for its Sculptura™ system by late 2022.
FAQ
What is the current stock price of Sensus Healthcare (SRTS)?
What is the market cap of Sensus Healthcare (SRTS)?
What is Sensus Healthcare, Inc.?
What products does Sensus Healthcare offer?
What is Superficial Radiation Therapy (SRT)?
Where is Sensus Healthcare based?
What recent collaborations has Sensus Healthcare announced?
How does Sensus Healthcare generate its revenue?
What is the Sentinel service program?
When is the next conference call for Sensus Healthcare?
Where can I find more information about Sensus Healthcare?
What conditions can Sensus Healthcare’s devices treat?
